Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care
| Autor: | Mohammed M. Milhem, Claire F. Verschraegen, Andrew E. Chapman, Edith P. Mitchell, Randall F. Holcombe, Martha P. Mims, Dan Mulkerin, Srinivasan Vijayakumar, Richard M. Goldberg, David K. Gaffney, Ruben A. Mesa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Health Personnel MEDLINE Translational research Article Translational Research Biomedical 03 medical and health sciences Preclinical research 0302 clinical medicine Cancer Medicine Neoplasms Physicians medicine Humans 030212 general & internal medicine business.industry Cancer medicine.disease Research Personnel Call to action Clinical research Oncology 030220 oncology & carcinogenesis Family medicine Patient Care business Healthcare providers |
| Zdroj: | J Natl Compr Canc Netw |
| Popis: | Background: Translation of basic discoveries to clinical care for patients with cancer is a difficult process greatly enabled by physician-trained researchers. Three categories of physicians, with responsibilities spanning from laboratory and preclinical research to direct patient care, are involved in the translational research continuum: physician-scientist (PS), clinician investigator (CI), and academic clinician (AC). Methods: To define how protected time for research efforts is supported, the Association of American Cancer Institutes (AACI) conducted a survey of their member institutions, obtaining 56 responses documenting time spent in research and clinical activities across multiple cancer disciplines, and providing information about funding streams for the different categories of cancer physicians. Results: Responses showed that PSs and ACs are minimally involved in clinical research activities; the driver or clinical research in academic cancer centers is the CI. A significant concern was a lack of stable funding streams for nonbillable clinical research activities, putting the sustainability of the CI in jeopardy. Limited funding was derived from hospital sources, with most support derived from cancer center sources. Conclusions: This study highlights the importance of the CI in translational cancer medicine and represents a call to action for institutions and research funding agencies to develop new programs targeted toward CI support to ensure continued progress against cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|